Allied Health & Imaging · Independent exam preparation
Certified Histocompatibility Technologist (CHT): Interpretation and Laboratory Decisions Study Guide
Practise HLA typing, antibody interpretation, crossmatch decisions and quality investigations with 60 focused CHT concepts, case questions and recall cards.
By CertMedbry · Updated 31 October 2026
Build the reasoning needed to assess specimen suitability, interpret HLA and antibody results, investigate discordance and release defensible laboratory reports. These 60 selected concepts connect assay mechanisms with practical decisions across all five CHT domains. The official ACHI CHT content outline defines the full examination scope; use it alongside this selective guide to identify additional study needs.
Try 20 free practice questionsWhat is the exam format?
Check the question types, timing and outline before planning your revision.
Which certification and level does this guide cover?
This guide covers the Certified Histocompatibility Technologist (CHT) examination administered by the American College of Histocompatibility and Immunogenetics (ACHI). The handbook also covers the Certified Histocompatibility Associate (CHA) and Certified Histocompatibility Specialist (CHS), but those are separate credentials. The CHT outline governs this guide; the CHS and laboratory director outlines are separate documents.
ACHI Resource Hub · ACHI Examination Candidate Handbook — January 2026
How many questions are scored, and how many are pretest questions?
The January 2026 handbook specifies 150 scored questions plus 20 unscored pretest questions, for 170 questions altogether. Pretest questions are interspersed throughout the examination and do not affect pass/fail status. Scored questions have equal weight.
How much testing time is available?
CHT candidates receive 3.5 hours of testing time. The handbook describes a four-hour appointment that includes an additional half hour for instructions and related activities. Tutorial time is outside the timed examination.
How is the examination delivered, and what question styles are verified?
The examination is computer delivered through Pearson VUE test centers, with an OnVUE remote-proctoring option for CHT candidates. The handbook describes four-option multiple-choice questions, presented one at a time, with bookmarking, backward navigation and answer changes during the time limit. It does not describe computer-adaptive testing. The 20 questions here are independent single-best-answer drills and do not predict passing.
Which blueprint and dates apply?
The CHT outline linked by ACHI and confirmed on October 30, 2026 assigns 18 scored items to Pre-Analytical Systems, 37 to Analytical Systems, 26 to Post-Analytical Systems, 36 to Quality Systems and 33 to General Theory and Applications. These correspond to calculated shares of 12%, 24.67%, 17.33%, 24% and 22%. The outline prints no effective date; its filename marker 20250321 does not establish one. The accompanying handbook explicitly states a January 2026 update.
ACHI Resource Hub · Certified Histocompatibility Technologist Exam Content Outline · ACHI Examination Candidate Handbook — January 2026
What eligibility and jurisdiction distinctions matter?
The handbook requires qualifying baccalaureate-level education and at least one year of relevant full-time histocompatibility laboratory experience completed within the specified five-year period for CHT. It describes verification through ASHI-, EFI- or CAP-accredited laboratories and a special-sponsorship process for some other settings. CHA and CHS requirements differ. CLIA examples in this guide concern U.S. laboratories subject to CLIA; accreditation and local requirements must be distinguished from those federal rules.
ACHI Examination Candidate Handbook — January 2026 · 2025 ASHI Standards — CMS approved January 27, 2026
Is there a verified universal passing percentage?
The handbook describes Angoff standard setting and statistical equating, but the supplied material does not establish a universal numerical passing percentage. Regular score reports include pass/fail status, the raw score and the score needed to pass. The handbook states that there is no penalty for guessing.
Which examination windows are stated?
The handbook's examination table lists May and November windows. A nearby administration sentence also mentions September, creating an internal inconsistency. Use ACHI's current scheduling instructions and the appointments available after authorization to establish your actual window.
This independent preparation guide addresses ACHI's Certified Histocompatibility Technologist credential. CHA, CHS and laboratory director examinations have separate eligibility or scope requirements. ACHI was formerly ABHI; the organization changed its name in October 2020.
Outline used: Current CHT Exam Content Outline linked by ACHI on 2026-10-13; filename revision marker 20250321, with no effective date printed in the outline. Accompanied by the Examination Candidate Handbook explicitly updated January 2026. The workbook label matches the official credential; the assigned slug is preserved.
60 key concepts: understand, apply and avoid the traps
Work through the questions by exam domain. Explain the answer in your own words, try the example, then check the common pitfall.
Pre-Analytical Systems12% (18/150 items; calculated)
1.How do specimen identifiers establish a defensible patient link?
Specimen identity must remain linked to the patient through collection, accessioning, processing and reporting. Compare the required identifiers on the primary container with the request and laboratory record before testing. A mismatch creates uncertainty about whose biological material is being analyzed, even when the analytical result appears plausible. Resolve the discrepancy through documented identification procedures; a familiar HLA pattern or an urgent transplant schedule cannot establish specimen identity.
Apply it
A tube carries the expected name but a different patient number from the request. Keep it segregated from accepted specimens, document the discrepancy and obtain an authorized resolution before using its results for compatibility assessment.
Common pitfall: Choosing the identifier that agrees with historical typing can conceal a collection error. Analytical agreement does not independently prove the source of a mislabeled specimen.
2.Which collection requirements follow from the assay's biological target?
Collection requirements depend on whether testing needs serum antibodies, intact viable lymphocytes or recoverable nucleic acid. An additive suitable for one purpose may interfere with another assay or fail to preserve the required target. Select the specimen type, container, volume and transport conditions from the validated method before collection. Suitability is therefore a relationship between the specimen and its intended assay, rather than a universal property of a blood tube.
Apply it
One collection is requested for antibody testing and a cell-based crossmatch. Confirm the separate serum and cell requirements before dispatching supplies, because a specimen adequate for antibody analysis may not provide suitable donor lymphocytes.
Common pitfall: A previously accepted tube type is not automatically acceptable for a new method. Additives, target stability and cell viability must match the specific assay.
2025 ASHI Standards — CMS approved January 27, 2026 · Certified Histocompatibility Technologist Exam Content Outline
3.Why can a specimen remain useful for DNA typing but fail a cell-based assay?
DNA recovery and viable-cell recovery assess different properties. Damaged cells may still contain amplifiable DNA, while a physical crossmatch needs an acceptable cell preparation and method-specific viability. Cell death can also increase nonspecific background or invalidate cytotoxicity interpretation. Evaluate processing time, transport conditions, viability and DNA quality against the intended method. Successful amplification does not demonstrate that the same specimen can support reliable testing with intact lymphocytes.
Apply it
An aged donor specimen produces adequate DNA but poor lymphocyte viability. Molecular typing may remain technically acceptable, while the crossmatch requires a suitable cell preparation or another validated approach with its limitation clearly communicated.
Common pitfall: Do not extend one assay's acceptance decision to every test on the specimen. Amplifiable DNA and functional cell preparations have different acceptance criteria.
2025 ASHI Standards — CMS approved January 27, 2026 · UCSF Immunogenetics and Transplantation Laboratory — Crossmatch Testing
4.How should aliquoting and storage preserve interpretability?
Storage conditions must preserve the analyte over the laboratory's validated interval. Separate aliquots can reduce repeated handling and freeze-thaw exposure while retaining material for repeat testing or investigation. Record specimen identity, collection timing, processing history and storage location so that an archived result remains traceable. Temperature alone does not establish suitability: container integrity, elapsed time and the number of handling events can also affect whether a stored specimen remains fit for use.
Apply it
A sensitized candidate's serum will support current testing and possible later comparison. Prepare identified aliquots under the laboratory's validated storage conditions and retain their processing history so repeat studies can be interpreted against the original collection.
Common pitfall: A freezer location is not a complete storage record. An unlabeled aliquot or unknown handling history can invalidate otherwise well-preserved biological material.
5.How does inventory traceability protect continuity of testing?
Inventory control links available supplies with lot identity, expiration, storage requirements and expected demand. Tracking these attributes prevents an apparent stock surplus from hiding unusable material. It also allows affected runs to be identified when a lot problem emerges. Review consumption and replacement lead times for critical reagents, and distinguish stock received from stock qualified for patient testing. Availability becomes operationally meaningful only when suitability and traceability are established.
Apply it
An urgent typing service has several kits on the shelf, but most expire before the next testing period. Count usable, qualified inventory and arrange replacement before the service depends on stock that cannot be released for testing.
Common pitfall: Ordering only when the shelf is empty ignores lot qualification and delivery time. Conversely, excessive stock can increase expiration losses without improving testing readiness.
42 CFR 493.1252 — Test Systems, Reagents and Supplies · Certified Histocompatibility Technologist Exam Content Outline
6.How do reconstitution calculations connect to reagent preparation?
Reconstitution converts a supplied material into a working reagent with a defined concentration and preparation history. For a simple dilution, C1V1 = C2V2 relates stock concentration and stock volume to final concentration and final volume. The diluent volume is the final volume minus the stock volume. Follow specified diluent and preparation conditions, then label and document the preparation. Correct arithmetic cannot compensate for an unsuitable diluent, inaccurate transfer or unsupported storage interval.
Apply it
Prepare 10 mL of a 0.1 mol/L solution from a 1 mol/L stock. Transfer 1 mL of stock and add suitable diluent to a final volume of 10 mL, then record preparation and expiry information.
Common pitfall: Adding 10 mL of diluent to 1 mL of stock produces 11 mL total. The required final volume includes the stock aliquot.
Certified Histocompatibility Technologist Exam Content Outline · 42 CFR 493.1252 — Test Systems, Reagents and Supplies
7.Which assay and equipment characteristics determine fitness for purpose?
Select an assay by the clinical question, required resolution, sensitivity, limitations and turnaround needs. Then select equipment and consumables that support its validated operating conditions. A pipettor must perform adequately at the actual transfer volume; a centrifuge setting must provide the required separation conditions. More detailed typing or greater analytical sensitivity is useful only when it answers the intended question and produces an interpretable result within the required workflow.
Apply it
A workflow requires repeated low-volume transfers near the bottom of a large pipettor's range. Choose a suitable calibrated pipettor for that volume rather than assuming that any device capable of displaying it provides equivalent performance.
Common pitfall: Selecting the most sensitive assay or highest-resolution method automatically can add delay or ambiguity. Fitness depends on the decision the result must support.
Certified Histocompatibility Technologist Exam Content Outline · CMS — CLIA Verification of Performance Specifications
Analytical Systems24.67% (37/150 items; calculated)
8.How do PCR-SSP controls distinguish a negative target from a failed reaction?
PCR with sequence-specific primers produces amplification when the primer-target combination supports the intended reaction. An internal control helps establish that a target-negative well had adequate amplification conditions. A missing target band with an acceptable control can contribute a negative reaction to the typing pattern. A missing target and missing control cannot be interpreted the same way. Assign the genotype from the complete validated reaction pattern rather than from one isolated band.
Apply it
One SSP well lacks both its target band and expected internal-control band. Treat that reaction as unresolved and investigate amplification performance before using it as evidence that the corresponding target sequence is absent.
Common pitfall: Calling every blank target lane negative can convert amplification failure into a false genotype. Control acceptance must precede interpretation of the target pattern.
9.How do primers and probes contribute different information?
Primers define and initiate amplification of a nucleic-acid region, whereas probes detect complementary sequences within an assay's analytical design. A probe-positive signal establishes recognition of its target under validated conditions; it does not necessarily identify one unique HLA allele. Heterozygosity and shared sequence motifs require interpretation across the full reaction pattern. Distinguish the sequence feature directly detected from the broader allele assignment inferred by the assay's analysis system.
Apply it
Several alleles share a sequence recognized by one probe. When that probe is positive, compare the complete probe pattern and ambiguity list rather than reporting whichever allele is most familiar from previous patient results.
Common pitfall: A positive probe is not automatically an allele-specific result. Shared motifs and two alleles at a locus can produce several compatible genotype interpretations.
Certified Histocompatibility Technologist Exam Content Outline · 2025 ASHI Standards — CMS approved January 27, 2026
10.Why can sequence-based HLA typing retain phase ambiguity?
A diploid specimen contains two alleles at most HLA loci. Detecting sequence variants does not always establish which variants lie together on the same chromosome. Different allele pairs can therefore explain the same unphased observations. Resolution depends on the regions examined and whether the method links informative variants. Additional sequencing or another validated discriminatory method can resolve an ambiguity only if it supplies information that separates the remaining alternatives.
Apply it
Two allele pairs fit the observed sequence, differing in how variants are distributed between chromosomes. Review the unresolved positions and select a method that establishes the necessary linkage rather than repeating the same uninformative region.
Common pitfall: More sequence reads do not necessarily resolve phase. Repeatedly observing the same unlinked variants can increase confidence in an observation without distinguishing allele pairs.
2025 ASHI Standards — CMS approved January 27, 2026 · HLA Nomenclature — Naming Alleles
11.When does HLA typing resolution meet the intended purpose?
Typing resolution describes which allele distinctions the result can make. A broad assignment may be adequate for one application while another requires discrimination between protein-distinct alleles or clarification of expression. Review the requested use against the method's coverage and unresolved alternatives. Reporting additional digits without supporting sequence discrimination does not create higher resolution. The useful endpoint is a supported assignment that answers the matching or identification question at hand.
Apply it
A matching request requires discrimination between two protein-distinct alleles that remain within the current result. Order an appropriate additional typing step and retain the existing ambiguity until the distinguishing evidence is available for review.
Common pitfall: Do not infer resolution from the apparent length of a reported name alone. Ambiguity, grouped reporting and unexamined regions determine what was actually distinguished.
HLA Nomenclature — Naming Alleles · 2025 ASHI Standards — CMS approved January 27, 2026
12.How do antibody screening and specificity analysis answer different questions?
An antibody screen evaluates reactivity against the antigen representation and detection conditions of that assay. Specificity analysis examines which HLA targets best explain the observed binding pattern. Neither task alone establishes donor specificity: that requires comparison with the particular donor's HLA information. Interpret positive and negative findings within assay coverage, controls and interference checks. A broad positive screen establishes reactivity, whereas a defensible specificity assignment identifies a supported target pattern.
Apply it
A recipient's screen becomes positive before a donor is identified. Characterize the antibody specificities first; when donor typing becomes available, compare those assignments with the donor rather than labeling the initial screen donor-specific.
Common pitfall: A positive screening result does not identify every antibody or prove incompatibility with every donor. A negative result also remains bounded by assay coverage.
UCSF Immunogenetics and Transplantation Laboratory — Crossmatch Testing · EDTA Treatment for Overcoming the Prozone Effect and for Predicting C1q Binding in HLA Antibody Testing
13.What does single-antigen bead fluorescence actually measure?
Single-antigen bead testing measures an assay-dependent fluorescence signal associated with antibody binding to bead-presented HLA. Mean fluorescence intensity is influenced by antibody binding, antigen presentation, reagent conditions and interference. It is not a standardized antibody concentration or a direct measurement of graft injury. Evaluate the specificity pattern, controls, specimen treatment and donor relationship together. An isolated signal value cannot by itself establish the biological effect of the detected antibody.
Apply it
Two sera show similar fluorescence for one specificity but differ after dilution and interference evaluation. Interpret each using the complete analytical pattern rather than concluding that identical untreated fluorescence establishes equal antibody strength or clinical risk.
Common pitfall: Treating fluorescence as an absolute antibody quantity ignores assay context. A higher signal may reflect analytical conditions rather than a proportionate increase in pathogenic potential.
14.How does cPRA describe the breadth of sensitization?
Calculated panel-reactive antibody estimates the percentage of donors in the reference population expected to carry at least one listed unacceptable HLA antigen. Its inputs are unacceptable-antigen assignments, combined with population HLA frequencies. A higher cPRA generally indicates a more restricted compatible donor pool under those assignments. It does not measure antibody concentration, specify the result for one donor or express the probability that a particular transplant will experience rejection.
Apply it
A candidate has cPRA of 98%, but an offered donor lacks the listed unacceptable antigens. Evaluate that donor's actual HLA and current antibody information; the population estimate does not establish that this individual donor is incompatible.
Common pitfall: Do not interpret cPRA as a rejection percentage or a physical crossmatch result. Its meaning depends on the unacceptable-antigen list and reference donor population.
15.How does a complement-dependent cytotoxicity crossmatch detect reactivity?
A complement-dependent cytotoxicity crossmatch exposes donor lymphocytes to recipient serum and evaluates cell injury after complement is added. Its endpoint therefore depends on antibody binding, complement activation and acceptable cell preparation. Controls help distinguish meaningful cytotoxicity from poor baseline viability or other technical effects. The result reflects the conditions of that method; a negative CDC crossmatch does not establish that every potentially relevant donor-reactive antibody is absent.
Apply it
Donor cells show substantial death even in the negative-control condition. Investigate cell preparation and baseline viability before attributing death in recipient-serum wells to a specific antibody-mediated crossmatch reaction under the validated test conditions.
Common pitfall: Cell death is not automatically evidence of donor-specific HLA antibody. Baseline viability, controls and the assay's dependence on complement must support that conclusion.
UCSF Immunogenetics and Transplantation Laboratory — Crossmatch Testing
16.How does a flow cytometric crossmatch differ from CDC testing?
A flow cytometric crossmatch detects antibody bound to donor cells using a fluorescent detection reagent and defined cell populations. With an anti-human IgG reagent, it assesses cell-bound IgG without requiring complement-mediated killing. Its greater analytical sensitivity relative to CDC can reveal binding when CDC remains negative. Interpret the fluorescence shift against validated controls and thresholds, while considering cell quality, nonspecific binding and any relevant treatment-related interference.
Apply it
A recipient has a positive flow crossmatch but negative CDC crossmatch with acceptable controls. Recognize that detectable cell-bound IgG need not produce cytotoxicity under CDC conditions, then correlate the result with antibody specificity and donor typing.
Common pitfall: Discordant flow and CDC results are not inherently contradictory. The methods measure different endpoints, so one cannot automatically invalidate the other without further investigation.
UCSF Immunogenetics and Transplantation Laboratory — Crossmatch Testing
17.Which information makes a virtual crossmatch interpretable?
A virtual crossmatch compares the recipient's characterized HLA antibodies with the donor's HLA type rather than physically combining serum and donor cells. Its reliability depends on adequate donor typing, relevant antibody coverage and a specimen history that reflects the recipient's sensitization status. Missing loci, unresolved typing or intervening sensitizing events can limit the inference. The analytical task is to establish whether supported antibody specificities correspond to antigens actually carried by that donor.
Apply it
A recipient has antibody to a donor locus that was not included in the available typing. Obtain the missing donor information or state the unresolved assessment; absence of a typed result cannot establish absence of its antigen.
Common pitfall: A virtual crossmatch cannot compensate for missing donor targets or outdated recipient information. A software comparison is only as complete as its underlying data.
UCSF Immunogenetics and Transplantation Laboratory — Crossmatch Testing
18.How do T-cell and B-cell crossmatch patterns guide investigation?
T lymphocytes express HLA class I, while B lymphocytes express class I and class II. A B-cell-positive, T-cell-negative pattern can therefore be consistent with class II-directed antibody. It is not specific proof, because differences in antigen expression, assay sensitivity and nonspecific effects can also shape the pattern. Compare cell-subset findings with donor HLA, the recipient's antibody specificities and assay controls before assigning an immunological explanation.
Apply it
A B-cell crossmatch is positive while the T-cell result is negative. Review class II antibody findings and the donor's class II typing, while checking B-cell background and controls before identifying the reaction as donor-specific.
Common pitfall: Equating every B-cell-only positive result with class II donor-specific antibody bypasses important alternatives. Cell population patterns are discriminatory clues, not stand-alone specificity assignments.
UCSF Immunogenetics and Transplantation Laboratory — Crossmatch Testing · Thermo Fisher Scientific — MHC Tetramer Technology
19.How do forward and reverse ABO grouping complement each other?
Forward grouping tests red cells for A and B antigens using defined reagents. Reverse grouping tests plasma or serum against reagent red cells to identify the expected antibody pattern. These complementary observations provide a consistency check rather than duplicate measurements of the same analyte. Interpret both with attention to age, immune status, transfusion history and other relevant findings. A discrepancy requires investigation before assigning an ABO conclusion for the intended transplant decision.
Apply it
Patient red cells react as group A, but reverse testing lacks the expected pattern. Review the testing and relevant history and investigate the discrepancy rather than selecting the forward result solely because its reactions appear stronger.
Common pitfall: Forward and reverse grouping are not interchangeable. One assesses red-cell antigens and the other circulating antibodies, so agreement must be evaluated rather than assumed.
HRSA OPTN — Guidance for Addressing Blood Type Determination
20.Which STR markers are informative for donor chimerism?
An informative short tandem repeat marker distinguishes donor-derived from recipient-derived DNA in the donor-recipient pair being monitored. Pretransplant comparison identifies markers whose allele patterns permit that distinction. Shared alleles may be less useful or require a validated calculation that accounts for overlap. Chimerism analysis therefore depends on pair-specific informativeness, assay performance and specimen composition. A polymorphic marker in the population is not necessarily informative for a particular transplant pair.
Apply it
Donor and recipient have identical alleles at one STR locus but distinguishable patterns at another. Use adequately informative loci for quantitative interpretation rather than expecting the shared locus alone to separate donor and recipient contributions.
Common pitfall: A strong electrophoretic signal does not make a marker informative. The essential feature is distinguishability between the actual donor and recipient, not peak height.
Mayo Clinic Laboratories — Chimerism Transplant Sorted Cells
21.Why does lineage selection change chimerism interpretation?
Whole-blood chimerism combines DNA from several leukocyte populations, whereas sorted-cell testing evaluates a selected lineage. Different lineages can have different donor contributions after transplantation, so the results answer related but distinct questions. Interpretation requires the cell fraction, sorting quality and comparison with prior measurements of the same fraction. A change in specimen composition can alter the aggregate donor percentage without representing an equivalent change in every lineage.
Apply it
Whole blood shows high donor chimerism while a selected T-cell fraction shows a lower value. Report each with its specimen fraction and compare like fractions over time instead of averaging them into a single unqualified percentage.
Common pitfall: Whole-blood and sorted-lineage percentages cannot be substituted freely. Differences may reflect biological compartmentalization or fraction purity rather than an analytical contradiction between valid measurements.
Mayo Clinic Laboratories — Chimerism Transplant Sorted Cells
22.How do genotype and antigen phenotype differ in non-HLA typing?
A molecular typing assay detects defined genetic features, whereas phenotyping examines expressed antigen or a related observable property. Genotype may explain a phenotype, but the two methods do not directly measure the same target. Interpretation depends on variant coverage, expression and specimen composition. For non-HLA systems such as ABO, use molecular findings within their validated purpose and investigate disagreements with serology rather than treating either result as an automatic substitute for the other.
Apply it
An ABO molecular result appears inconsistent with serologic grouping after a recent transfusion. Review the target detected, specimen sources and transfusion history, then investigate the discrepancy before using a genotype label as the complete serologic explanation.
Common pitfall: Detecting a genetic variant does not directly demonstrate its expressed antigen pattern. Limited variant coverage and mixed cell populations can complicate genotype-phenotype comparisons.
HRSA OPTN — Guidance for Addressing Blood Type Determination · 2025 ASHI Standards — CMS approved January 27, 2026
Post-Analytical Systems17.33% (26/150 items; calculated)
23.Why can EDTA treatment reveal stronger HLA antibody reactivity?
Complement-related interference can suppress antibody detection in single-antigen bead testing, producing an unexpectedly low untreated signal. EDTA chelates divalent cations needed for complement activity and can reduce this interference under validated assay conditions. Increased signal after treatment can therefore reveal previously masked binding rather than newly created antibody. Compare treated and untreated patterns with appropriate controls. Treatment improves interpretation of a specific analytical problem; it does not convert fluorescence into an absolute antibody concentration.
Apply it
A strongly sensitized recipient has unexpectedly weak untreated bead results that rise substantially after EDTA treatment. Investigate complement interference and reassess the specificity pattern rather than concluding that the treatment caused the patient to develop new antibodies.
Common pitfall: The term prozone does not explain every weak result. EDTA addresses complement-related interference and cannot correct absent antigen coverage or every source of assay error.
24.How should a result near an antibody interpretation threshold be assessed?
A threshold translates an analytical signal into a laboratory interpretation under defined conditions. Values near that boundary are particularly sensitive to analytical variation, background and specimen treatment. Review the specificity pattern, controls, reproducibility and relevant donor information before drawing a strong conclusion from a small numerical difference. A threshold is an operational decision rule for a validated assay; it is not a universal biological boundary between harmless and harmful antibody.
Apply it
A bead signal moves slightly across the laboratory's interpretation threshold on repeat testing while the broader pattern remains stable. Evaluate analytical variability and context before describing the change as a definite new sensitization event in the report.
Common pitfall: A tiny numerical threshold crossing does not establish a meaningful biological change. Conversely, a below-threshold result should not override clear evidence of assay interference.
EDTA Treatment for Overcoming the Prozone Effect and for Predicting C1q Binding in HLA Antibody Testing · 2025 ASHI Standards — CMS approved January 27, 2026
25.How should unresolved HLA typing alternatives be reported?
An unresolved typing result should preserve the alternatives supported by the analytical data and explain any limitation relevant to its use. First distinguish a genuine method-related ambiguity from failed controls or poor-quality data. Additional testing should target the information needed to discriminate among the remaining possibilities. If the ambiguity affects matching or another requested decision, communicate that consequence explicitly. Choosing the most common allele pair does not resolve an analytically unresolved result.
Apply it
Two supported allele pairs differ in a clinically relevant matching assignment. Retain both possibilities, explain the unresolved distinction and arrange discriminatory testing rather than releasing only the more frequent pair as a confirmed genotype to the transplant team.
Common pitfall: Population frequency can inform interpretation but cannot replace missing discriminatory evidence. A plausible allele pair is not necessarily the uniquely established result of the assay.
2025 ASHI Standards — CMS approved January 27, 2026 · HLA Nomenclature — G Groups
26.Why must HLA expression suffixes survive interpretation and reporting?
An HLA expression suffix adds information beyond the numbered allele fields. For example, N denotes a null allele, while L indicates low cell-surface expression; other defined suffixes describe additional expression states. Omitting a suffix can erase a distinction relevant to interpreting antigen expression and compatibility. Preserve the complete supported designation and distinguish established expression information from an unresolved alternative. Sequence similarity alone does not justify assuming identical expression for every related allele.
Apply it
A typing alternative includes an allele carrying the N suffix. Before summarizing the alternatives as equivalent, determine whether the unresolved expression distinction matters for the requested assessment and preserve that limitation in the final laboratory report.
Common pitfall: Do not treat expression suffixes as optional formatting. Removing them can change the biological meaning of an otherwise correctly copied HLA allele designation.
HLA Nomenclature — Naming Alleles · HLA Nomenclature — G Groups
27.How should a new HLA result that conflicts with history be investigated?
A historical mismatch can arise from identification error, analytical limitations, transcription problems or a biological change in the source of tested cells. Hematopoietic transplantation is especially relevant because circulating cells may be donor derived. Compare specimen identity, collection timing, tissue source, methods and original records before deciding which result represents the intended patient genotype. Repeating the same extraction can assess reproducibility but cannot independently exclude a specimen-source or identification problem.
Apply it
Blood typing after hematopoietic transplantation differs from a pretransplant record. Review donor information and the intended genetic question, then select an appropriate specimen source if the patient's constitutional HLA type must be established for the requested purpose.
Common pitfall: Neither the newest result nor the oldest result automatically controls. The correct interpretation depends on specimen origin, transplant history and the question being answered.
Mayo Clinic Laboratories — Chimerism Transplant Sorted Cells · 2025 ASHI Standards — CMS approved January 27, 2026
28.How does an autocrossmatch help investigate unexpected cell binding?
An autocrossmatch tests recipient serum against the recipient's own cells and can help characterize reactivity that is not uniquely directed at donor HLA. A positive result supports investigation of autoreactivity or other broadly acting cell-binding effects, but it does not by itself identify their cause. Review cell controls, antibody findings and relevant treatment history together. An autocrossmatch is an investigative comparison; it neither proves nor excludes every form of donor-specific antibody.
Apply it
Several donor crossmatches are positive despite no corresponding HLA specificity, and an autocrossmatch is also positive. Investigate broadly reactive or nonspecific binding and relevant treatment effects rather than assigning an unsupported donor-specific HLA antibody to each donor.
Common pitfall: A positive autocrossmatch does not make every donor reaction clinically irrelevant. Separate the explanation for background reactivity from any independently supported donor-specific antibody.
UCSF Immunogenetics and Transplantation Laboratory — Crossmatch Testing · 2025 ASHI Standards — CMS approved January 27, 2026
29.Which clues guide investigation of an ABO discrepancy?
An ABO discrepancy is a disagreement within or between expected antigen and antibody findings. Begin with specimen identity, reagent performance and technical review, then examine relevant history such as recent transfusion, transplantation, age or altered immune function. These factors can affect red-cell populations or expected antibodies through different mechanisms. Document the unresolved findings and their consequences for the requested use. A group assignment should reflect a resolved interpretation rather than majority voting among reactions.
Apply it
Mixed red-cell reactions appear after a documented transfusion. Confirm identification and technical performance, then investigate the possibility of more than one red-cell population while keeping the transplant team informed of the unresolved ABO determination and its limitations.
Common pitfall: Repeating the same grouping without reviewing history may reproduce the discrepancy without explaining it. Strong reactions do not automatically outweigh a biologically important mixed-field finding.
HRSA OPTN — Guidance for Addressing Blood Type Determination
30.What makes a histocompatibility report actionable and traceable?
For U.S. CLIA laboratories, 42 CFR 493.1291(c) requires positive patient identification; the name and address of the laboratory location performing the test; the report date; the test performed; the specimen source when appropriate; the result and applicable units, interpretation, or both; and information about the condition and disposition of specimens that fail laboratory acceptability criteria. Positive patient identification can include the patient's name and identification number. Additional histocompatibility details explain the result's meaning: typing resolution and unresolved ambiguity, crossmatch cell population, or the sorted-cell fraction used for chimerism. These interpretive details supplement the required report elements.
Apply it
A report states 82% donor DNA. Verify the required patient identification, performing laboratory information, report date, test, appropriate specimen source and result information. Specify that the measurement used sorted CD3-positive cells so a clinician can compare it with prior T-cell chimerism rather than mistake it for whole-blood chimerism.
Common pitfall: A specimen source such as peripheral blood does not identify a sorted-cell fraction. Likewise, adding a detailed interpretation does not compensate for missing patient identification or the performing laboratory's name and address.
42 CFR 493.1291 — Test Report · Mayo Clinic Laboratories — Chimerism Transplant Sorted Cells
31.How should an erroneous released report be corrected?
When a released result is found erroneous, the correction must be communicated and traceable. U.S. CLIA reporting rules require prompt notification of the ordering person and, when applicable, the person using the result, followed by corrected reports. Preserve the original and corrected information so the sequence can be reconstructed. Evaluate whether the error affected clinical decisions or other reports. Replacing a displayed value without documenting and communicating the correction leaves an unsafe information gap.
Apply it
A released donor HLA report contains a transcribed allele error. Notify the ordering and relevant clinical users promptly, issue a clearly identified corrected report and retain the original report with the documented correction and investigation record.
Common pitfall: Silently overwriting the result does not ensure that recipients stop using the earlier report. A correction requires communication as well as an accurate replacement.
32.When must a testing delay or alert result be communicated?
Communication requirements depend on the result's urgency and the consequences of delay. U.S. CLIA rules require immediate alerting for results indicating an imminently life-threatening condition or designated panic or alert values. When established reporting time frames cannot be met, assess whether notification is needed based on the urgency of testing. In transplant work, explain what remains unresolved and its expected impact on reporting rather than implying that incomplete findings establish compatibility.
Apply it
A time-sensitive crossmatch is delayed by failed controls. Notify the responsible clinical team that a valid result is unavailable, explain the testing issue and expected reporting update, and document communication while the laboratory resolves the analytical failure.
Common pitfall: Urgency does not make an invalid result reportable as final. Equally, waiting silently for troubleshooting can deprive clinicians of information needed to plan safely.
Quality Systems24% (36/150 items; calculated)
33.Which laboratory activities require aerosol containment?
Procedures that can generate infectious aerosols require controls selected through risk assessment. Opening specimen containers, vigorous mixing and centrifugation-related handling can create exposure opportunities. A suitable biological safety cabinet protects personnel during appropriate aerosol-generating work, while sealed centrifuge containment helps control another route of release. Select containment for the biological hazard and procedure. A clean-air device intended mainly to protect a product does not automatically provide equivalent protection to the worker.
Apply it
A workflow adds vigorous mixing of potentially infectious primary specimens. Assess aerosol generation and establish suitable containment and handling practices before routine use, including how centrifuge containers will be opened and how exposed surfaces will be decontaminated.
Common pitfall: A visually clean workspace does not establish aerosol safety. Product protection, personnel protection and environmental containment are different functions that must be evaluated explicitly.
CDC — Guidelines for Safe Work Practices in Human and Animal Medical Diagnostic Laboratories
34.Why are gloves insufficient without hand hygiene?
Gloves reduce direct contact with potentially infectious material, but they can become contaminated, develop defects or transfer contamination to clean surfaces. Hand hygiene remains necessary after glove removal and at other indicated points in laboratory work. Change gloves when contaminated or when moving between incompatible tasks, and keep laboratory protective equipment within its designated use. Effective protection combines barriers with correct removal, hygiene and control of what contaminated hands touch.
Apply it
After handling specimens, a technologist removes gloves and prepares to use a shared computer outside the testing area. Perform hand hygiene first and avoid carrying contaminated protective clothing or equipment into the clean workspace during the transition.
Common pitfall: Wearing the same gloves continuously can spread contamination across keyboards, phones and door handles. Gloves are task-specific barriers rather than a substitute for clean hands.
CDC — Guidelines for Safe Work Practices in Human and Animal Medical Diagnostic Laboratories
35.How should a biological spill response match the exposure mechanism?
A spill response must address the material, location, aerosol potential and any associated sharps or chemical hazards. Restrict access as appropriate, use suitable protective equipment and apply the laboratory's validated decontamination procedure. Exposure management is a separate task from cleaning the surface: splashes, sharps injuries or mucous-membrane contact require prompt reporting and assessment. The correct sequence prevents cleanup from creating additional exposure while preserving necessary incident information.
Apply it
A specimen tube breaks near the centrifuge and leaves visible fragments. Control access, assess aerosol and sharps hazards, and use the established spill procedure with tools for debris handling rather than collecting broken glass by gloved hand.
Common pitfall: Immediate barehanded or improvised cleanup can amplify exposure. Removing visible fluid alone also leaves sharps, contaminated surfaces and possible personnel exposure insufficiently addressed.
CDC — Guidelines for Safe Work Practices in Human and Animal Medical Diagnostic Laboratories
36.Which reagent labeling and storage details are essential?
In U.S. CLIA laboratories, reagents and supplies must be handled under requirements covering identity, storage and expiration, with labeling information such as concentration when applicable and dates relevant to preparation and use. Maintain lot traceability and follow conditions that preserve performance. Expired, deteriorated or substandard material must not be used for patient testing. A reagent can be present and correctly named yet remain unsuitable because its preparation or storage history is incomplete.
Apply it
A working solution has a name and concentration but no preparation or expiration information. Establish its documented preparation history and authorized usability before patient testing; otherwise replace it with a properly prepared and labeled solution for the assay.
Common pitfall: Acceptable control results do not automatically authorize expired or inadequately identified reagents. Compliance and traceability requirements remain separate from a single run's apparent performance.
37.Why should a new reagent lot be evaluated before routine use?
A reagent lot change can alter signal strength, background or other performance characteristics even when the product name is unchanged. Evaluate the new lot using the laboratory's defined acceptance procedure before relying on it for patient testing. Relevant materials should challenge the aspects of performance most likely to affect interpretation. Record the lot, evaluation and acceptance decision so later shifts can be connected to the change rather than mistaken for patient biology.
Apply it
A new antibody-testing lot shows higher background in weakly reactive material than the current lot. Investigate the comparison against established acceptance criteria before release, and determine whether interpretation or additional evaluation is required for the intended patient testing.
Common pitfall: A manufacturer's release does not establish performance in every local workflow. Conversely, one discrepant specimen needs investigation rather than automatic rejection of the entire lot.
2025 ASHI Standards — CMS approved January 27, 2026 · 42 CFR 493.1252 — Test Systems, Reagents and Supplies
38.How do controls establish whether patient results are interpretable?
Controls challenge defined parts of the analytical process and establish whether a run meets acceptance criteria. Positive, negative and internal controls answer different questions, such as whether detection works, background is acceptable or amplification occurred. Review the relevant controls before interpreting patient results. A failed control requires investigation and appropriate corrective action; apparently plausible patient patterns cannot independently demonstrate that the failed part of the system performed adequately.
Apply it
A crossmatch positive control fails while patient samples appear negative. Withhold conclusions dependent on adequate detection, investigate the control failure and repeat the affected testing under acceptable conditions before reporting donor-recipient compatibility from that analytical run.
Common pitfall: Accepting patient results because they fit expectations defeats the purpose of independent controls. A failed positive control specifically weakens confidence in negative findings.
42 CFR 493.1282 — Corrective Actions · One Lambda Micro SSP Typing Trays
39.How does accuracy verification differ from simply obtaining expected controls?
Accuracy verification evaluates agreement with appropriate reference or comparative results across material relevant to the assay's intended use. Routine controls alone may not represent the breadth of patient results, variants or interpretive boundaries. For an unmodified FDA-cleared or approved nonwaived test, U.S. CLIA verification requirements differ from establishing performance for a modified or laboratory-developed method. Define the applicable study and acceptance criteria before implementation rather than interpreting a few successful runs as complete verification.
Apply it
A laboratory introduces an unmodified qualitative test. Compare suitable known positive and negative specimens with established results and document the required performance verification, rather than relying solely on the kit controls supplied with the first testing run.
Common pitfall: Repeatability of one control does not establish accuracy across the intended result categories. Verification must address the actual method and its applicable regulatory status.
40.What does precision mean for a qualitative histocompatibility assay?
Precision concerns consistency when the same material is tested repeatedly under specified conditions. For a qualitative assay, examine reproducibility of the categorical interpretation, including material near a decision boundary when relevant. Replicates across runs, days or operators can evaluate different sources of variation. Precision does not establish that the repeated result is correct. A method may consistently misclassify a specimen, so precision and accuracy require distinct evidence during performance evaluation.
Apply it
A weakly reactive specimen alternates between positive and negative across operators while strong controls remain stable. Investigate variability near the interpretation boundary and assess whether the method's precision is adequate for its intended qualitative use in patient testing.
Common pitfall: Identical repeated results demonstrate consistency, not necessarily truth. Evaluating only strong positives and clear negatives can miss instability near a clinically important decision boundary.
41.How do sensitivity and specificity summarize different classification errors?
Diagnostic sensitivity is the proportion of reference-positive specimens classified positive, while diagnostic specificity is the proportion of reference-negative specimens classified negative. Their denominators therefore differ. False negatives reduce sensitivity; false positives reduce specificity. Interpret both with the reference method, specimen selection and intended use in mind. These classification measures are also distinct from analytical sensitivity, which concerns the amount or level of analyte a method can detect under defined conditions.
Apply it
A comparison includes 40 reference-positive specimens, of which 38 test positive, and 60 reference-negative specimens, of which 57 test negative. Calculate sensitivity as 38/40 and specificity as 57/60; both equal 95% in this study.
Common pitfall: Dividing true positives by all tested specimens does not calculate sensitivity. Also distinguish classification performance against a reference from the assay's analytical detection capability.
CMS — CLIA Verification of Performance Specifications · Certified Histocompatibility Technologist Exam Content Outline
42.How do calibration and routine QC serve different purposes?
Calibration establishes or adjusts the relationship between instrument response and assigned values. Routine quality control monitors whether the test system continues to perform within established acceptance limits. The activities are related but not interchangeable: successful QC does not necessarily demonstrate correct response across the entire reportable range, and calibration alone does not establish sustained day-to-day stability. Apply procedures appropriate to the test system rather than transferring quantitative calibration assumptions indiscriminately to qualitative HLA assays.
Apply it
A quantitative instrument has acceptable midrange QC after adjustment. Review the required calibration and range-verification activities separately before concluding that results near both ends of the reportable range remain adequately supported for patient reporting in that system.
Common pitfall: One acceptable control concentration cannot establish performance across an entire quantitative range. Calibration, calibration verification and routine QC answer related but different performance questions.
42 CFR 493.1255 — Calibration and Calibration Verification Procedures
43.When is calibration verification required for applicable quantitative systems?
For quantitative test systems subject to U.S. CLIA calibration-verification requirements, document verification across the reportable range, including a minimal or zero value, a midpoint value and a maximum value. Perform verification at least every six months and after a complete reagent change unless the laboratory demonstrates that reagent lot changes do not affect the reportable range or adversely affect control values. Additional triggers include major preventive maintenance or replacement of critical parts that may influence performance. Unusual control trends, shifts or unacceptable values also trigger verification when other corrective approaches fail to identify and correct the problem. Follow manufacturer instructions and any more frequent laboratory-established schedule.
Apply it
After replacing a critical analyzer component that could affect response, verify the applicable system across its reportable range. A passing midrange control alone does not establish acceptable performance at the range limits. For a complete reagent change, either perform verification or have documented evidence supporting the specified reagent-lot exception.
Common pitfall: Calibration verification checks whether the existing calibration remains valid; it does not necessarily require recalibration. Preserve the applicability qualification: this rule is not a universal six-month recalibration requirement for every qualitative histocompatibility assay.
42 CFR 493.1255 — Calibration and Calibration Verification Procedures
44.How should unexpected results and established quality failures be investigated?
An unexpected patient result requires assessment before it is classified as a laboratory failure. Under 42 CFR 493.1281, laboratories must identify, assess and document relevant inconsistencies with clinical information, other results or expected relationships. Assessment may establish that an unusual result is biologically valid. Separately, 42 CFR 493.1282 requires documented corrective action for failures involving established test-system performance specifications, acceptable control or calibration results, or required storage conditions. For an established failure, correct the problem, establish acceptable performance before reporting affected results, and evaluate whether patient results obtained since the last acceptable run were adversely affected.
Apply it
New HLA antibody reactivity after a sensitizing event warrants comparison with previous specimens, donor typing, treatment history and assay controls; coherent new specificity with acceptable performance may represent a true immune response. A control shift after a reagent change instead establishes a quality problem requiring investigation, correction, verification of restored performance and assessment of affected patient results.
Common pitfall: Unexpected biology does not itself prove analytical error. Conversely, a passing repeat does not explain an earlier control failure or establish that previously released results were unaffected. Document the assessment and any corrective actions as distinct conclusions.
Federal Register :: Request Access · 42 CFR 493.1282 — Corrective Actions
45.How does workflow separation reduce molecular contamination?
Amplified nucleic acid can contaminate subsequent reactions and create false-positive signals. Separating reagent preparation, specimen processing and post-amplification activities reduces opportunities for carryover, especially when equipment and supplies follow controlled movement. Negative controls help detect contamination within their coverage, but prevention remains central. Investigate the location and pattern of contamination before resuming testing. A clean negative control does not exclude every specimen-specific mix-up or contamination event.
Apply it
Unexpected amplification appears in a no-template control after post-PCR materials were handled near reagent preparation. Stop interpreting the affected run, investigate carryover routes and restore the designated workflow before repeating testing with acceptable controls and documented corrective action.
Common pitfall: Changing the negative control alone can hide the symptom while leaving contaminated reagents or work areas in use. Address the source and affected scope.
2025 ASHI Standards — CMS approved January 27, 2026 · 42 CFR 493.1282 — Corrective Actions
46.Which records make a result reconstructable?
A reconstructable record links the patient and specimen to processing, reagent lots, equipment, analytical data, controls, interpretation, review and released reports. The required detail depends on the method, but the underlying principle is continuity from biological material to communicated conclusion. Preserve corrections and relevant communications as part of that history. Traceability supports discrepancy investigation and impact assessment; it is more than retaining a final result in a patient database.
Apply it
A reagent lot is later found defective. Use run records to identify affected specimens, controls, interpretations and reports, then assess the defined group rather than searching only for patients whose final results happened to appear unusual.
Common pitfall: Keeping only the final report prevents reconstruction of how the result was obtained. Missing lot or run links can make a targeted recall impossible.
2025 ASHI Standards — CMS approved January 27, 2026 · 42 CFR 493.1291 — Test Report
47.How do quality indicators turn recurring errors into process improvement?
A quality indicator measures a defined aspect of performance using a stable numerator, denominator and review interval. Examples relevant to histocompatibility include specimen-identification discrepancies, amended reports and delayed urgent results. Examine trends and contributing processes, implement a focused change and reassess the same measure. Counts alone can mislead when workload changes. Improvement requires evidence that the process performs better, rather than merely documenting that staff were reminded to be careful.
Apply it
Identification discrepancies rise from 4 among 800 specimens to 8 among 800. Review the increase from 0.5% to 1%, identify where errors originate and reassess the rate after a targeted collection or accessioning change is implemented.
Common pitfall: A lower error count may reflect fewer specimens rather than better performance. Changing definitions during follow-up also makes before-and-after comparisons unreliable for improvement assessment.
2025 ASHI Standards — CMS approved January 27, 2026 · Certified Histocompatibility Technologist Exam Content Outline
General Theory and Applications22% (33/150 items; calculated)
48.How do MHC class I and class II differ in antigen presentation?
MHC class I presents peptide to CD8 T cells, whereas MHC class II presents peptide to CD4 T cells. Class I is broadly expressed on nucleated cells; class II is characteristically expressed on professional antigen-presenting cells, including B cells. These relationships connect molecular target, cell distribution and immune recognition. They help explain both T-cell assay design and why T-cell and B-cell crossmatch patterns can differ without directly identifying the responsible antibody.
Apply it
A peptide-MHC reagent is designed to identify CD8 T cells recognizing a defined peptide. Select an appropriate class I peptide-MHC complex and understand that binding identifies receptor specificity rather than proving that the cells killed a target.
Common pitfall: Class designation does not refer to antibody isotype. Also distinguish peptide-MHC recognition by T cells from HLA antibody binding measured in transplant antibody assays.
49.How does haplotype inheritance explain sibling matching probabilities?
A child ordinarily inherits one HLA haplotype from each parent. Under the simplified model of two distinct parental haplotypes per parent and no recombination, another full sibling has a 25% chance of inheriting the same pair, a 50% chance of sharing exactly one and a 25% chance of sharing neither. These are probabilities before testing, not confirmed assignments. Actual family typing is needed to establish the inherited combinations and investigate exceptions.
Apply it
Two full siblings are being considered as donors. Explain that each has an individual chance of matching the patient's inherited haplotype pair, then use actual HLA typing rather than assigning match status from birth order or family resemblance.
Common pitfall: The 25% probability does not mean exactly one of every four siblings must match. Independent inheritance outcomes can produce several matches or no matches.
50.How do linkage disequilibrium and recombination affect HLA inference?
Physical linkage makes nearby loci more likely to be inherited together. Linkage disequilibrium describes population allele combinations occurring at frequencies different from those expected under independent association. Recombination can separate linked variants and produce a new inherited combination. These concepts support interpretation of family and population patterns but do not establish an individual's untested allele. Statistical association is a clue for evaluating an assignment, while direct typing or segregation evidence supplies individual confirmation.
Apply it
A family result does not fit the common population haplotype associated with one allele. Review the analytical data and parental segregation, considering recombination rather than changing the observed result solely to reproduce the more frequent population combination.
Common pitfall: A common haplotype is not an obligatory haplotype. Linkage disequilibrium cannot replace individual testing, and unusual segregation should prompt investigation rather than automatic dismissal.
Certified Histocompatibility Technologist Exam Content Outline · NMDP — HLA Typing and Matching
51.What information is encoded in the fields of an HLA allele name?
An HLA allele designation begins with the locus and uses colon-separated numerical fields. The first field identifies the allele group. The second distinguishes protein sequence differences; the third distinguishes synonymous coding differences; the fourth distinguishes differences in noncoding regions. Additional expression suffixes convey defined information beyond these fields. Read the fields according to their biological meaning rather than treating every added number as an equivalent change in protein structure or clinical relevance.
Apply it
Two alleles share their first two fields but differ in the third. Recognize a synonymous coding distinction rather than assuming the names encode different HLA proteins; still report the result at the supported resolution required for its use.
Common pitfall: A different third or fourth field does not necessarily mean a different amino-acid sequence. Expression suffixes also cannot be inferred solely from field count.
52.Which sequence identity does an HLA G group establish?
An HLA G group contains alleles with identical nucleotide sequences across the exons encoding the peptide-binding domains: exons 2 and 3 for class I and exon 2 for class II. It does not establish identity across the entire gene. Alleles grouped this way may differ elsewhere, including regions relevant to expression. Interpret a G-group assignment as a defined sequence grouping and determine whether unexamined distinctions matter for the intended application.
Apply it
A G-group result includes alternatives with differences outside the peptide-binding exons. Check whether those differences affect the requested assessment, especially expression-related distinctions, rather than expanding the group designation into an unsupported claim of whole-gene identity for every member.
Common pitfall: G means identity across specified nucleotide regions, not universal equivalence of all gene features. It should not be confused with a protein-based grouping.
53.Why can a secondary immune response outpace a primary response?
A primary adaptive response begins with activation and expansion of antigen-responsive lymphocytes. Subsequent exposure can recruit memory populations established during earlier sensitization, allowing a faster and often stronger response. In histocompatibility interpretation, this explains why current low or undetectable circulating antibody does not erase the relevance of a documented antibody history. Distinguish the concentration detected in today's specimen from the immune system's capacity to respond again after antigen exposure.
Apply it
A recipient previously had a defined HLA antibody that is not detected in the latest specimen. Preserve that history when assessing donor information, because a current negative measurement does not demonstrate loss of antigen-specific immune memory in the recipient.
Common pitfall: Do not equate an undetectable antibody result with proof that the recipient was never sensitized. Current assay findings and immunological memory describe different states.
Certified Histocompatibility Technologist Exam Content Outline · UCSF Immunogenetics and Transplantation Laboratory — Crossmatch Testing
54.How do sensitizing events change the relevance of an antibody specimen?
Exposure to nonself HLA through events such as transplantation, transfusion or pregnancy can contribute to alloimmunization. An antibody specimen represents the immune findings at its collection time, so events after collection may change how well it represents the current recipient. Review the timing of the sample, prior antibody findings and relevant interval history when assessing compatibility. An analytically valid older result can still be temporally incomplete for a new donor assessment.
Apply it
A virtual crossmatch uses serum collected before a subsequent transfusion. Review the interval history and obtain an appropriately current assessment under the laboratory's protocol rather than assuming the earlier antibody profile remains sufficient solely because its testing was valid.
Common pitfall: Specimen analytical quality does not establish current immunological relevance. Conversely, an exposure history alone does not prove that a particular new antibody has developed.
UCSF Immunogenetics and Transplantation Laboratory — Crossmatch Testing · Certified Histocompatibility Technologist Exam Content Outline
55.Why can antibodies persist after plasma antibody removal or CD20-directed B-cell depletion?
Removing antibody-containing plasma reduces circulating antibody but leaves antibody-producing cells capable of replenishing it. Rituximab binds CD20 on pre-B and mature B lymphocytes and promotes their lysis through mechanisms including complement-dependent and antibody-dependent cellular cytotoxicity. Long-lived antibody-producing plasma cells generally lack CD20 and therefore are not directly eliminated by rituximab. Their continued antibody secretion explains persistence despite substantial B-cell depletion, as supported by the [original antibody-persistence study](https://pubmed.ncbi.nlm.nih.gov/18085668/). This ongoing production is distinct from antibody already circulating when treatment begins and from later responses involving surviving or recovering lymphocyte populations.
Apply it
After plasma exchange, an early antibody decline reflects removal from the circulating compartment. Subsequent persistence or rebound can reflect continued production by surviving plasma cells. After rituximab, a depleted peripheral B-cell count can coexist with detectable HLA antibody because CD20-negative plasma cells remain. Interpret serial antibody findings alongside specimen timing, treatment history and assay conditions.
Common pitfall: Neither a low B-cell count nor a falling single-antigen bead signal demonstrates elimination of long-lived plasma cells or durable antigen-specific tolerance. EDTA-responsive complement interference changes antibody detection within the assay; it does not demonstrate therapeutic removal of antibody or depletion of its producing cells.
Certified Histocompatibility Technologist Exam Content Outline · EDTA Treatment for Overcoming the Prozone Effect and for Predicting C1q Binding in HLA Antibody Testing · 103705s5467lbl.pdf
56.How does immune tolerance differ from generalized immunosuppression?
Immune tolerance is reduced or absent responsiveness to a particular antigenic target within an otherwise responsive immune system. Generalized immunosuppression reduces immune activity more broadly. The distinction matters when interpreting an apparently quiet clinical or laboratory state: lack of detectable antibody or injury does not by itself demonstrate antigen-specific tolerance. Interpret the evidence at the level actually measured, separating a current assay observation from a claim about the recipient's overall immune mechanism.
Apply it
A stable transplant recipient has no detectable donor-specific antibody while receiving immunosuppression. Report the laboratory finding as measured rather than labeling the recipient tolerant solely because antibody testing is negative and current clinical function is stable.
Common pitfall: Absence of one detectable immune marker is not a mechanistic test of tolerance. Suppressed activity, assay limits and antigen-specific unresponsiveness are different possible explanations.
Certified Histocompatibility Technologist Exam Content Outline
57.How should HLA-B27 be interpreted in relation to ankylosing spondylitis?
HLA-B27 is associated with ankylosing spondylitis, but a positive result alone is not diagnostic. An association identifies a relationship between a genetic finding and disease; it does not mean that every carrier develops that disease. Interpretation therefore depends on the reason for testing and the accompanying clinical findings. Report HLA-B27 detection accurately while keeping the genetic result distinct from a diagnosis. The cited laboratory test information explicitly describes HLA-B27 testing for ankylosing spondylitis as not diagnostic.
Apply it
In an asymptomatic person, a positive HLA-B27 result establishes the detected HLA finding without establishing ankylosing spondylitis. During evaluation of a patient with relevant symptoms, such as persistent inflammatory back pain, the same positive result can support the clinical assessment alongside examination and imaging findings. Its interpretive value changes with the clinical context even though the genetic finding is the same.
Common pitfall: Avoid reporting 'ankylosing spondylitis confirmed' from HLA-B27 positivity. Association is not absolute penetrance, and a genetic test does not supply the patient's symptoms, examination findings or imaging evidence. Do not assign an unsupported numerical disease risk to an individual carrier.
Certified Histocompatibility Technologist Exam Content Outline · HLA Nomenclature — Naming Alleles · HLA B27
58.Why must abacavir screening specifically resolve HLA-B*57:01?
HLA-B*57:01 is associated with increased risk of abacavir hypersensitivity. Abacavir prescribing information requires screening before initiation, and HLA-B*57:01 positivity contraindicates abacavir. A first-field HLA-B*57 result identifies an allele group and does not establish whether HLA-B*57:01 is present. The assay must specifically distinguish the requested target from relevant alternatives and have appropriate validated coverage. A negative HLA-B*57:01 result does not eliminate hypersensitivity risk or the need for clinical vigilance.
Apply it
A patient being considered for abacavir has an existing report showing HLA-B*57 without further resolution. Obtain a validated result that resolves HLA-B*57:01 status before treating that report as the required screen. If HLA-B*57:01 is detected, communicate the drug-specific contraindication. If it is absent, explain that the result addresses this genetic risk factor rather than guaranteeing freedom from hypersensitivity.
Common pitfall: Do not extend the HLA-B*57:01 association to every HLA-B*57 allele or use an unresolved group result as a negative screen. The label directs immediate discontinuation if hypersensitivity is suspected regardless of genotype; abacavir must never be restarted following an abacavir hypersensitivity reaction.
HLA Nomenclature — Naming Alleles · CMS — CLIA Verification of Performance Specifications · Certified Histocompatibility Technologist Exam Content Outline · Table of Pharmacogenetic Associations | FDA · Abacavir Tablets, USP Rx Only These highlights do not include all the information needed to use ABACAVIR TABLETS safely and effectively. See full prescribing information for ABACAVIR TABLETS. Initial U.S. Approval: 1998
59.How are serial dilution factors combined?
A dilution factor is the final mixture volume divided by the volume of original material transferred into that mixture. Sequential dilution factors multiply because each step further reduces the fraction of original material. A 1:4 dilution followed by a 1:5 dilution yields a 1:20 overall dilution. Keep units and notation explicit, and distinguish preparation of a dilution from interpretation of the resulting assay signal, which may not respond linearly to antibody concentration.
Apply it
Mix 50 microliters of serum with 150 microliters of diluent, then transfer 40 microliters of that mixture into 160 microliters of diluent. The steps are 1:4 and 1:5, giving a final 1:20 serum dilution.
Common pitfall: Adding the step factors gives the wrong overall dilution. Also avoid assuming that a twentyfold dilution must produce a twentyfold decrease in bead fluorescence.
Certified Histocompatibility Technologist Exam Content Outline · EDTA Treatment for Overcoming the Prozone Effect and for Predicting C1q Binding in HLA Antibody Testing
60.How do molarity and mass concentration determine reagent amounts?
Molarity expresses moles of solute per liter of final solution. Calculate required mass as molarity multiplied by final volume in liters and molecular weight in grams per mole. Mass concentration uses units such as grams per liter and must not be substituted for molarity without conversion. Confirm the chemical form because a hydrate or salt can have a different molecular weight. Prepare to the final volume after dissolving the measured solute.
Apply it
To prepare 0.100 L of a 0.200 mol/L solution with molecular weight 50 g/mol, calculate 0.200 × 0.100 × 50 = 1.00 g. Dissolve that mass and bring the solution to 100 mL final volume.
Common pitfall: Using milliliters directly in a formula requiring liters creates a thousandfold error. Molecular weight must also correspond to the actual chemical form being weighed.
Certified Histocompatibility Technologist Exam Content Outline
What to focus on during revision
The following are CertMedbry study suggestions. Use the official outline to check the full scope of your examination.
- Allocate study time using the official item counts: Analytical Systems and Quality Systems together account for 73 of 150 scored items.
- Connect each assay with its target, controls, measured endpoint, resolution and limitations before interpreting a patient result.
- Practise distinguishing HLA antibody specificity, donor specificity, cPRA and physical crossmatch findings.
- Investigate discordance through specimen identity, biological source, analytical interference and method differences.
- Learn exact HLA field, expression-suffix and G-group meanings; preserve clinically relevant ambiguity.
- Apply U.S. CLIA requirements with their stated scope, especially reporting corrections, corrective actions and quantitative calibration verification.
- Calculate dilutions, molarity and performance percentages with explicit denominators and units.
- Use the complete official outline to extend beyond these 60 selected concepts.
A practical preparation plan
1. Map the complete outline
Create a five-domain study map from the official CHT outline. Mark each listed topic as secure, developing or unfamiliar, then give Analytical Systems and Quality Systems the largest combined share of review.
2. Build assay comparison sheets
Compare SSP, sequence-based typing, antibody assays, CDC, flow crossmatch, virtual crossmatch, ABO grouping and STR monitoring by specimen, target, controls, endpoint and unresolved limitations.
3. Work through discrepancies
For each case, state the decisive observation, plausible mechanisms, the evidence needed to distinguish them and the reporting consequence. Include failed controls, EDTA-responsive interference, typing ambiguity and post-transplant specimen changes.
4. Practise quality decisions
Review reagent acceptance, verification, calibration applicability, corrective-action scope and corrected reports. Explain why a passing repeat does or does not resolve the original problem and previously released results.
5. Complete and explain the drills
Answer the 20 questions, then explain why each alternative is less appropriate. Use missed concepts to direct review rather than interpreting the drill score as an examination pass prediction.
6. Retrieve and calculate regularly
Use the flashcards for active recall and practise dilution, molarity, sensitivity, specificity and percentage calculations. Finish each session by checking unresolved topics against the full official outline.
Use your sample score as a starting point
The free set contains 20 original practice questions. It is a small learning sample, not an official examination or a validated pass prediction. Review each explanation and its source before moving to another topic.
Start the free sampleOfficial sources and updates
- ACHI Resource Hub
- ACHI Examination Candidate Handbook — January 2026
- Certified Histocompatibility Technologist Exam Content Outline
- 2025 ASHI Standards — CMS approved January 27, 2026
- HLA Nomenclature — Naming Alleles
- HLA Nomenclature — G Groups
- One Lambda Micro SSP Typing Trays
- Mayo Clinic Laboratories — Chimerism Transplant Sorted Cells
- HRSA OPTN — CPRA Calculator
- UCSF Immunogenetics and Transplantation Laboratory — Crossmatch Testing
- HRSA OPTN — Guidance for Addressing Blood Type Determination
- EDTA Treatment for Overcoming the Prozone Effect and for Predicting C1q Binding in HLA Antibody Testing
- 42 CFR 493.1291 — Test Report
- 42 CFR 493.1252 — Test Systems, Reagents and Supplies
- 42 CFR 493.1282 — Corrective Actions
- CMS — CLIA Verification of Performance Specifications
- CDC — Guidelines for Safe Work Practices in Human and Animal Medical Diagnostic Laboratories
- 42 CFR 493.1255 — Calibration and Calibration Verification Procedures
- NMDP — HLA Typing and Matching
- Thermo Fisher Scientific — MHC Tetramer Technology
- G Groups
- What is HLA? HLA Basics, Typing & Matching Overview | NMDP
- Table of Pharmacogenetic Associations | FDA
- Abacavir Tablets, USP Rx Only These highlights do not include all the information needed to use ABACAVIR TABLETS safely and effectively. See full prescribing information for ABACAVIR TABLETS. Initial U.S. Approval: 1998
- 103705s5467lbl.pdf
- HLA B27
- Federal Register :: Request Access
- Abacavir Tablets, USP Rx Only These highlights do not include all the information needed to use ABACAVIR TABLETS safely and effectively. See full prescribing information for ABACAVIR TABLETS. Initial U.S. Approval: 1998
- HLA alleles and haplotypes observed in 263 US families - PubMed
- Characterization of recombination in the HLA class II region - PubMed
Confirm current eligibility, fees, scheduling and policies directly with the examination provider. CertMedbry is independent and is not endorsed by these organisations. How we handle content and corrections.